Shrivastava Nikita, Jena Rahul, Choudhary Gautam Ram, Bhargava Priyank, Vishwajeet Vikarn, Elhence Poonam, Singh Mahendra, Bhirud Deepak Prakash, Sandhu Arjun Singh
Department of Urology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India.
Department of Pathology, All India Institute of Medical Sciences, Jodhpur, India.
J Cancer Res Clin Oncol. 2023 Nov;149(17):15795-15804. doi: 10.1007/s00432-023-05348-z. Epub 2023 Sep 5.
The molecular mapping of cancers by the Cancer Genome Atlas Project has accelerated the quest for new therapeutic targets for urinary bladder cancer, including sex steroid receptors. Previous studies have demonstrated conflicting results on their relationship with bladder cancer, and there is sparse data on their expression in the Indian population. The aim of our study is to examine the expression of androgen receptors (AR) and estrogen receptors (ERα and ERβ) in patients with bladder cancer and their correlation with clinicopathologic features.
In this retrospective cohort study, a total of 132 patients, who were surgically managed for urinary bladder mass by transurethral resection or radical cystectomy in our institute, with transitional cell carcinoma on histopathology and with at least two years of follow-up were included. Their demographic and treatment details were obtained, histopathology blocks were retrieved and immunohistochemical staining for androgen and estrogen receptors was performed. Then, the relationship between their expression and clinicopathologic features was studied.
A total of 3.79% of patients showed estrogen receptor alpha positivity, 51.52% estrogen receptor beta positivity and 63.64% androgen receptor positivity. No statistically significant correlation was found between age of patients (p = 0.75/0.52/0.87), tumour stage and grade (0.71/0.3/0.21), pathological variant (p = 1/0.58/0.38) and overall survival (p = 0.70/0.052/0.45 for NMIBC and p = 0.82/0.36/0.22) and estrogen receptor alpha, estrogen receptor beta and androgen receptor-positive status, respectively. Estrogen receptor beta positivity was significantly higher in patients with unifocal (p = 0.015) and small tumours (< 5 cm) (p = 0.03), and its expression was associated with better disease-free survival (DFS) (p = 0.046) in patients of non-muscle invasive bladder cancer (NMIBC).
Our study has the largest sample size conducted on Indian population with results differing from previous studies conducted on western population. Estrogen receptor beta expression was significantly associated with small unifocal tumours and better DFS. Estrogen receptor alpha and androgen receptor expression were not found to be associated with the clinicopathologic features of the study population.
癌症基因组图谱计划对癌症进行的分子图谱分析加速了对膀胱癌新治疗靶点的探索,其中包括性类固醇受体。以往的研究在它们与膀胱癌的关系上得出了相互矛盾的结果,并且关于它们在印度人群中的表达的数据很少。我们研究的目的是检测膀胱癌患者中雄激素受体(AR)和雌激素受体(ERα和ERβ)的表达及其与临床病理特征的相关性。
在这项回顾性队列研究中,纳入了在我们研究所通过经尿道切除术或根治性膀胱切除术接受手术治疗膀胱肿物的132例患者,其组织病理学诊断为移行细胞癌且至少有两年的随访时间。获取了他们的人口统计学和治疗细节,检索了组织病理学切片并进行了雄激素和雌激素受体的免疫组织化学染色。然后,研究了它们的表达与临床病理特征之间的关系。
共有3.79%的患者雌激素受体α呈阳性,51.52%雌激素受体β呈阳性,63.64%雄激素受体呈阳性。患者年龄(p = 0.75/0.52/0.87)、肿瘤分期和分级(0.71/0.3/0.21)、病理类型(p = 1/0.58/0.38)以及总生存期(非肌层浸润性膀胱癌(NMIBC)的p = 0.70/0.052/0.45,以及p = 0.82/0.36/0.22)与雌激素受体α、雌激素受体β和雄激素受体阳性状态之间均未发现有统计学意义的相关性。单灶性(p = 0.015)和小肿瘤(<5 cm)(p = 0.03)患者中雌激素受体β阳性率显著更高,并且在非肌层浸润性膀胱癌(NMIBC)患者中其表达与更好的无病生存期(DFS)相关(p = 0.046)。
我们的研究是针对印度人群进行的样本量最大的研究,结果与之前针对西方人群进行的研究不同。雌激素受体β的表达与小的单灶性肿瘤以及更好的DFS显著相关。未发现雌激素受体α和雄激素受体的表达与研究人群的临床病理特征相关。